Company Overview
BioNexus Gene Lab Corp. operates as a specialized supplier within the Basic Materials sector, specifically focusing on the Specialty Chemicals industry in Southeast Asia. The company and its subsidiaries are dedicated to the sale of chemical raw materials essential for manufacturing a diverse range of industrial products, including those for medical, appliance, automotive, mechanical, and electronic applications across Malaysia, Indonesia, Vietnam, and other regional markets. This specialized operational focus positions the firm as a critical upstream provider supporting downstream manufacturing sectors in the region. As of the latest reporting period, the company holds a market capitalization of $5.55M, generates annual revenue of $9.47M, and maintains an employee count of 30. These financial figures indicate that BioNexus Gene Lab Corp. functions as a micro-cap entity with a relatively small operational footprint compared to larger industrial peers, reflecting a niche market position rather than broad market dominance. The modest revenue scale combined with a low employee count suggests a highly specialized business model reliant on specific chemical supply chains rather than economies of scale typical of larger diversified chemical producers.
Financial Health
The company reported revenue of $9.47M over the trailing twelve-month period, yet recorded a net income of $-2,296,809 and an EBITDA of $-2,333,958. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses, likely including raw material procurement and manufacturing overhead, exceed gross profits by a wide margin. Additionally, the free cash flow stands at $-2,021,792, indicating that the company is currently burning cash rather than generating liquidity, which limits its financial flexibility for capital expenditures or debt repayment without external financing. Marginal analysis shows a gross margin of 14.8%, suggesting that for every dollar of sales, the company retains $0.148 before operating expenses, while the operating margin of -30.3% and profit margin of -24.3% highlight severe inefficiencies in covering fixed costs and overhead relative to sales volume. Regarding liquidity and leverage, the firm holds $2.89M in cash against total debt of $233,722, creating a nominal net cash position, though the debt-to-equity ratio of 3.43 indicates a highly leveraged capital structure relative to shareholder equity. The current ratio of 8.30 demonstrates strong short-term liquidity, as the company possesses more than eight times the current assets necessary to cover its current liabilities. However, the return on equity of -28.3% and return on assets of -16.4% reveal that management is currently destroying value for shareholders and failing to generate sufficient returns on the asset base deployed to support operations.
Valuation Assessment
Valuation metrics for BioNexus Gene Lab Corp. present a complex picture due to its lack of profitability, as the trailing P/E ratio and forward P/E are both listed as N/A. The absence of a positive earnings base means these traditional multiples cannot be calculated, implying that valuation is currently disconnected from earnings power and likely driven by asset values or speculative trading rather than operational performance. The price-to-book ratio is 0.62, indicating that the market values the company at less than its book value, which suggests investors are pricing in significant downside risk or expect substantial asset write-downs. Alternative valuation measures include a price-to-sales ratio of 0.59 and an EV/EBITDA of -0.67, both of which suggest the market is discounting the stock heavily due to the negative earnings trajectory and cash burn. Price action over the last year has been highly volatile, with the 52-week high set at $15.60 and the 52-week low at $1.92. Without a specific current share price provided in the facts, the valuation context relies on these historical bounds to define the range of investor sentiment, where the stock has experienced a decline of over 88% from its peak. The beta of 2.28 signifies that the stock is more than twice as volatile as the broader market, meaning price swings are amplified relative to general market movements, increasing the risk profile for any holder.
Growth & Income
The company's revenue growth rate stands at -3.3% year-over-year, while earnings growth is listed as N/A due to the absence of prior period profitability. The negative revenue growth indicates a contraction in sales volume or pricing power, while the N/A earnings growth reflects the inability to calculate percentage change without a positive earnings baseline in the previous period. Regarding income distribution, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. This lack of dividend payments is consistent with the negative net income and negative free cash flow, as the company must retain all available resources to cover its operating deficits and debt obligations rather than returning capital. Consequently, the overall growth and income profile is characterized by declining revenue, a complete absence of dividend income, and negative operational returns, presenting a scenario typical of a distressed or turnaround-stage micro-cap chemical supplier.